Premium
La hepatotoxicidad inducida por fármacos antituberculosos es inesperadamente baja en pacientes VIH positivos con tuberculosis pulmonar, en Malawi
Author(s) -
Tostmann A.,
Boeree M. J.,
Harries A. D.,
Sauvageot D.,
Banda H. T.,
Zijlstra E. E.
Publication year - 2007
Publication title -
tropical medicine and international health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.056
H-Index - 114
eISSN - 1365-3156
pISSN - 1360-2276
DOI - 10.1111/j.1365-3156.2007.01871.x
Subject(s) - medicine , tuberculosis , drug , pulmonary tuberculosis , human immunodeficiency virus (hiv) , immunology , pharmacology , pathology
Summary The proportion of patients with antituberculosis drug‐induced hepatotoxicity (ATDH) was unexpectedly low during a trial on cotrimoxazole prophylaxis in Malawian HIV‐positive pulmonary tuberculosis patients. About 2% of the patients developed grade 2 or 3 hepatotoxicity during tuberculosis (TB) treatment, according to WHO definitions. Data on ATDH in sub‐Saharan Africa are limited. Although the numbers are not very strong, our trial and other papers suggest that ATDH is uncommon in this region. These findings are encouraging in that hepatotoxicity may cause less problem than expected, especially in the light of combined HIV/TB treatment, where drug toxicity is a major cause of treatment interruption.